EyePoint Pharmaceuticals anticipates a 9-month extension to Dexycu’s pass-through payment status, according to a press release.
The current pass-through payment status for Dexycu (dexamethasone intraocular suspension 9%) would expire on March 31, 2022, without an extension, the release said.
“We are extremely pleased that the CMS has indicated it intends to provide additional pass-through time, subject to public comment, allowing for another 9 months of pass-through status for important innovative products such as Dexycu,” Nancy Lurker, CEO of EyePoint Pharmaceuticals, said in